Pharmaceutical

FDA to start review of subcutaneous Entyvio for Crohn’s...

The FDA is also reviewing a subcutaneous formulation of Takeda’s blockbuster dru...

FDA calls out eight companies for selling unapproved ey...

The US Food and Drug Administration has sent letters to eight companies for unau...

Vaxess raises $9m to accelerate mRNA vaccine patch deve...

The patch allows for vaccine storage and transport at room temperature along wit...

Do diet drugs pull their weight?

Diet and weight-loss drugs have entered the public consciousness, particularly f...

Signal: Roche to refile subcutaneous Tecentriq with FDA...

Roche planned to launch its new subcutaneous Tecentriq formulation this year, bu...

CDC recommends updated Covid vaccines for everyone 6 mo...

A CDC analysis suggested that a universal recommendation for updated Covid vacci...

Food companies to regulators: Please don’t worry about ...

Food companies are pleading with regulators not to focus their attention on ultr...

STAT+: White House touts efforts to stem cancer drug sh...

The White House outlined its efforts to end shortages of three key generic chemo...

STAT+: Neurocrine Biosciences drug for congenital adren...

Neurocrine Biosciences announced on Tuesday that an experimental drug for congen...

Popular nasal decongestant doesn’t actually relieve con...

The leading decongestant used by millions of Americans looking for relief from a...

STAT+: Walmart may buy concierge Medicare Advantage pro...

Experts largely hailed Walmart's rumored acquisition of Medicare Advantage provi...

Is there a path forward for PEPFAR?

Lawmakers are growing less optimistic about a full-reauthorization for PEPFAR, t...

STAT+: Pharmalittle: Is Pascal Soriot leaving AstraZene...

AstraZeneca appeared to play down speculation about CEO Pascal Soriot after a U....

STAT+: Nick Leschly departs Bluebird Bio spinout amid r...

Some two years after splitting biotech company Bluebird Bio into two entities, t...

STAT+: New obesity drugs are in the works trying to out...

Hunting for the next Ozempic, dozens of companies are pursuing various combinati...

Opinion: Patients might finally receive practical infor...

The FDA can’t fall for these five myths that often undermine health communications.